0.25Open0.25Pre Close0 Volume1.01K Open Interest10.00Strike Price0.00Turnover279.39%IV160.15%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.2035Delta0.0938Gamma15.76Leverage Ratio-0.0156Theta0.0004Rho3.21Eff Leverage0.0031Vega
Alector Stock Discussion
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
Key point...
$Alector (ALEC.US)$
$PacWest Bancorp (PACW.US)$
Who will squeeze best?
All in or just a little?
$Viasat (VSAT.US)$ +5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor $L3Harris Technologies (LHX.US)$ for nearly $2 billion.)
$Myovant Sciences (MYOV.US)$ +31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
No comment yet